How to administer ZARXIO
Should patients need to self-inject, here’s a video on how to administer ZARXIO.
ZARXIO is available with a BD™ UltraSafe Passive® Needle Guard that provides one-handed passive activation.1

Not actual size.
ZARXIO strengths
ZARXIO is available in prefilled syringes, in the same 2 dosage strengths as NEUPOGEN® (filgrastim) and has an identical dosing schedule and route of administration to NEUPOGEN®.1,2

ZARXIO is administered by subcutaneous injection, short intravenous infusion (15 to 30 minutes)‚ or continuous intravenous infusion.1
You should not inject a dose of ZARXIO less than 0.3 mL (180 mcg) from a ZARXIO prefilled syringe. A dose less than 0.3 mL cannot be accurately measured using the ZARXIO prefilled syringe.1
Learn about ZIEXTENZO (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz3
G-CSF=granulocyte colony-stimulating factor.
BD is a trademark of Becton, Dickinson and Company.
UltraSafe Passive is a registered trademark of Safety Syringes, Inc.
NEUPOGEN is a registered trademark of Amgen Inc.
References: 1. ZARXIO Prescribing Information. Sandoz Inc. September 2022. 2. NEUPOGEN® Prescribing Information. Amgen Inc. April 2023. 3. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.